Interne link ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome maart 17, 2021 om 11:00 AM UTC
Interne link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference maart 02, 2021 om 09:30 PM UTC
Interne link ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results februari 25, 2021 om 12:00 PM UTC
Interne link ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome februari 16, 2021 om 09:30 PM UTC
Interne link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 januari 07, 2021 om 12:00 PM UTC
Interne link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa december 11, 2019 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa november 21, 2019 om 12:00 PM UTC
Interne link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 november 06, 2019 om 12:00 PM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares oktober 18, 2019 om 12:20 PM UTC
Interne link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares oktober 16, 2019 om 03:17 AM UTC
Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares oktober 15, 2019 om 09:15 PM UTC
Interne link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 oktober 15, 2019 om 08:08 PM UTC
Interne link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10 oktober 11, 2019 om 10:02 AM UTC
Interne link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients oktober 10, 2019 om 10:00 AM UTC
Interne link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO oktober 07, 2019 om 11:00 AM UTC
Interne link ProQR to Present at Two Investor Conferences in October september 30, 2019 om 11:00 AM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa september 09, 2019 om 11:00 AM UTC
Interne link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) augustus 12, 2019 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the Second Quarter of 2019 augustus 07, 2019 om 11:00 AM UTC
Interne link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 juli 29, 2019 om 04:37 PM UTC
Interne link European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 juli 29, 2019 om 11:00 AM UTC
Interne link ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July juli 02, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the JMP Securities Life Sciences Conference juni 03, 2019 om 11:00 AM UTC